Multiple sclerosis: three trials to watch
September and October 2025 have proven busy for multiple sclerosis (MS) professionals, as many gathered at three major conferences to…
Features
‘The time of the Einsteins is over’: Pharma urged to rethink trials for 2050
Pharma R&D set to endure despite rising MFN costs
Europe’s path to maintaining clinical trial hotbed of innovation
OS endpoint focus will realign industry to “ultimate goal”
Trials to watch: Three major catalysts in Alzheimer’s disease
What does the EU Data Act mean for businesses?
From humble to global: China’s biotechs navigate the demands of international trials
